These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19625653)

  • 1. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
    Barber A; Sentman CL
    J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
    Barber A; Rynda A; Sentman CL
    J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
    Barber A; Zhang T; Sentman CL
    J Immunol; 2008 Jan; 180(1):72-8. PubMed ID: 18097006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
    Zhang T; Sentman CL
    J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
    Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
    J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
    Barber A; Meehan KR; Sentman CL
    Gene Ther; 2011 May; 18(5):509-16. PubMed ID: 21209626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.
    Barber A; Zhang T; Megli CJ; Wu J; Meehan KR; Sentman CL
    Exp Hematol; 2008 Oct; 36(10):1318-28. PubMed ID: 18599182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    Helmich BK; Dutton RW
    J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
    Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
    Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    J Immunol; 2012 Jun; 188(12):6389-98. PubMed ID: 22586039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
    Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
    Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
    Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
    J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.